Group 1 - The core viewpoint of the news is that Guoen Technology, a Chinese chemical materials supplier, has successfully completed its IPO subscription, raising significant interest from investors with an oversubscription rate of 878 times [1] - Guoen Technology plans to issue 30 million H-shares, with 10% allocated for Hong Kong and 90% for international offerings, and has a total fundraising target of up to 1.26 billion HKD [1] - The company has attracted eight cornerstone investors, raising a total of approximately 320 million HKD [1] Group 2 - Guoen Technology, founded in 2000, specializes in chemical new materials and gelatin, serving both the chemical and health industries [2] - The company is the second-largest producer of bone gelatin in China and the largest domestic brand, as well as the second-largest domestic brand in the hollow capsule industry, according to Frost & Sullivan [2] - Financially, the company reported revenues of approximately 13.406 billion RMB, 17.439 billion RMB, 19.188 billion RMB, and 17.444 billion RMB for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [2] Group 3 - The net proceeds from the IPO are expected to be approximately 1.058 billion HKD, with 50% allocated to expanding production capacity in Thailand, 35% for new production capacity in China, 10% for investments in Hong Kong, and 5% for operational funds [3]

Group 1 - The core viewpoint of the article is that Guoen Technology, a Chinese chemical materials supplier, has successfully completed its IPO subscription, raising significant interest from investors with an oversubscription of 878 times the public offering amount [1] - Guoen Technology plans to issue 30 million H-shares, with 10% allocated for Hong Kong and 90% for international offerings, and a total fundraising target of up to HKD 1.26 billion [1] - The company has attracted eight cornerstone investors, with a total subscription amount of approximately HKD 320 million [1] Group 2 - Guoen Technology, founded in 2000, specializes in chemical new materials and gelatin, serving both the chemical and health industries [2] - The company is the second-largest producer of bone gelatin in China and the largest domestic brand in terms of production volume, as well as the second-largest domestic brand in the hollow capsule industry [2] - Financially, the company reported revenues of approximately RMB 134.06 billion, RMB 174.39 billion, RMB 191.88 billion, and RMB 174.44 billion for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [2] Group 3 - The net proceeds from the IPO are expected to be approximately HKD 1.058 billion, with 50% allocated to expanding production capacity in Thailand, 35% for new production capacity in China, 10% for investments in Hong Kong, and 5% for operational funds and general corporate purposes [3]

IPO 申购指南 国恩科技（2768.HK） 建议申购 2026-1-27 星期二 | 【招股详情】 | | | | --- | --- | --- | | 保荐人 | 招商证券国际 | | | 上市日期 | 年 2026 | 月 日（星期三） 2 4 | | 招股价格 | 34~42 | 港元/股（中间价：38 港元/股） | | 集资额 | 10.577 | 亿港元（扣除包销费及佣金，按中间价计算） | | 每手股数 | 200 股 | | | 入场费 | 8,484.71 | 港元 | | 招股日期 | 2026 年 | 1 月 27 日-2026 年 1 月 30 日 | | 国元证券认购截止日期 | 2026 年 | 1 月 29 日 | | 招股总数 | 3,000 | 万股(可予调整及视乎超额配售权的行使情况而定) | | 国际配售 | 2,700 | 万股(可予调整及视乎超额配售权的行使情况而定)，约占 90% | | 公开发售 | 300 | 万股(可予调整及视乎超额配售权的行使情况而定)，约占 10% | 【申购建议】 公司是一家专注于化工新材料及明胶、胶原蛋白上下游产品的中国供货商。 公 ...

Investment Rating - The report recommends subscription for the company, Guo'en Technology, with an IPO price range of HKD 34 to HKD 42 per share, suggesting a valuation of approximately 15 times the net profit for 2024 [3]. Core Insights - Guo'en Technology is a Chinese supplier focused on chemical new materials and gelatin, serving both the chemical and health industries. It ranks as the second-largest organic polymer modified materials and composite materials company in China by sales revenue, with a market share of 2.5% [2]. - The global polymer materials market is projected to grow from RMB 29.89 trillion in 2020 to RMB 45.61 trillion by 2024, with a compound annual growth rate (CAGR) of 11.1%. The Chinese polymer materials market is expected to expand from RMB 11.08 trillion in 2020 to RMB 16.28 trillion by 2024, with a CAGR of 10.1% [2]. - The company's revenue for 2022, 2023, and 2024 is forecasted to be RMB 13.41 billion, RMB 17.44 billion, and RMB 19.19 billion, respectively, reflecting a CAGR of 19.6%. Net profits for the same years are projected at RMB 663.11 million, RMB 465.89 million, and RMB 676.38 million [3]. Summary by Relevant Sections IPO Details - The IPO is set to raise HKD 10.577 billion, with a total offering of 30 million shares, of which 27 million shares are allocated for international placement and 3 million shares for public offering [1]. Market Position - Guo'en Technology is the second-largest producer of bone gelatin and the second-largest domestic brand producer of hollow capsules in China, indicating a strong market presence [2]. Financial Performance - The company is currently in a stable growth phase, with a significant safety margin in its valuation based on the IPO pricing compared to its A-share closing price [3].

Core Viewpoint - Guoen Technology (02768.HK) plans to globally offer 30 million H-shares, with 3 million shares available in Hong Kong and 27 million shares for international distribution, aiming for a price range of HKD 34.00 to 42.00 per share, with trading expected to commence on February 4, 2026 [2][3] Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [3] - The company operates in two main sectors: the large chemical sector, providing solutions to manufacturers in automotive, new energy, and home appliances, and the health sector, supplying raw materials for supplements and pharmaceuticals [3][4] Market Position - In the large chemical industry, Guoen is the second-largest company in China for organic polymer modified materials and organic polymer composite materials, holding a market share of 2.5% as of 2024 [4] - Guoen is also the largest producer of polystyrene in China by production capacity as of 2024 [4] Financial Performance - The company has shown strong revenue growth, with revenues of RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion for the fiscal years 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate (CAGR) of 19.6% from 2022 to 2024 [7] - The sales figures for the fiscal years 2023 and 2024 indicate year-on-year growth rates of 30.1% and 10.0%, respectively [7] Market Trends - The market for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion by 2024, with a CAGR of 15.7% [8] - The market is expected to continue strong growth, reaching RMB 1,037.5 billion by 2029, with a forecasted CAGR of 14.1% from 2025 to 2029 [8] Use of Proceeds - The net proceeds from the share offering are estimated at approximately HKD 1.057 billion, with plans to allocate 50% for establishing a new production base in Thailand, 35% for expanding capacity in Yixing, and 10% for investments in Hong Kong [9]

Group 1 - The core viewpoint of the news is that Guoen Technology (国恩科技) is preparing for its IPO in the Hong Kong market, with a strong foundation and significant fundraising expectations [2][4] - Guoen Technology plans to globally issue approximately 30 million H-shares, with 3 million shares allocated for public offering in Hong Kong and 27 million shares for international offering [2] - The expected net fundraising amount is approximately HKD 1.058 billion, with funds allocated for expanding production capacity in Thailand and China, as well as for operational purposes [2][4] Group 2 - Guoen Technology specializes in new chemical materials and collagen products, serving the chemical and health industries, focusing on R&D, production, and sales [4] - The company ranks second in the organic polymer modification and composite materials industry in China by sales revenue, with a market share of 2.5%, and is the largest producer of polystyrene in China [4] - In the health sector, Guoen Technology's subsidiary, Dongbao Biological, has established a complete layout from collagen raw materials to end products, becoming a comprehensive group in the health segment [4] Group 3 - For the fiscal years 2022 to 2024, Guoen Technology's revenues were RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion, with corresponding profits of RMB 0.724 billion, RMB 0.540 billion, and RMB 0.721 billion [5] - The company has shown solid performance in its financial results, indicating a stable growth trajectory [5]

Core Viewpoint - The company, Guoen Technology (02768), is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for capacity expansion and operational purposes [1][5]. Group 1: Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry and has established a vertically integrated product line from collagen to end products [3]. - The company ranks second in China's bone gelatin production by output and is the leading domestic brand in this category as of 2024 [3]. - It is also the second-largest domestic brand in the hollow capsule production market by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with key investors including Liguang Investment and others [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations of 50% for expanding production capacity in Thailand, 35% for capacity expansion in China, 10% for investments in Hong Kong, and 5% for operational funds [5].

Core Viewpoint - The company, Guo'en Technology, is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for expansion and operational purposes [1][5]. Group 1: Company Overview - Guo'en Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by production capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry, with a vertical integration strategy that spans from collagen to end products [3]. - The company is the second-largest producer of bone gelatin in China by output and the largest domestic brand in this category as of 2024 [3]. - It ranks as the second-largest domestic brand in the hollow capsule production sector in China by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with investors including several financial institutions [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations planned for expanding production capacity in Thailand (50%), China (35%), and investments in Hong Kong (10%) [5].

Group 1 - The company, Guoen Technology (02768.HK), plans to globally offer 30 million H-shares, with 3 million shares available in Hong Kong and 27 million shares for international distribution, with the offering period from January 27 to January 30, 2026, and expected pricing on February 2, 2026 [1] - The expected share price range is between HKD 34.00 and HKD 42.00, with a trading unit of 200 shares, and the shares are anticipated to start trading on the Hong Kong Stock Exchange on February 4, 2026 [1] - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving the chemical and health industries, focusing on R&D, production, and sales [1] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling approximately HKD 320 million, assuming a maximum share price of HKD 42.00 [2] - The cornerstone investors include several entities such as Liguan Investment Limited, SLD International Enterprises Limited, and others [2] Group 3 - Assuming a mid-range share price of HKD 38.00, the company estimates net proceeds from the global offering to be approximately HKD 1.0577 billion [3] - The company plans to allocate about 50% or HKD 528.5 million to establish a new production base in Thailand to expand capacity, 35% or HKD 370.5 million to enhance capacity at its Yixing production base, and 10% or HKD 105.7 million for investments in Hong Kong [3] - The remaining 5% or approximately HKD 53 million is expected to be used for working capital and general corporate purposes [3]

格隆汇1月27日丨国恩科技(02768.HK)发布公告，公司拟全球发售3000万股H股，中国香港发售股份300 万股，国际发售股份2700万股(以上可予重新分配)；2026年1月27日至1月30日招股，预期定价日为2月2 日；发售价每股发售股份34.00-42.00港元，H股的每手买卖单位将为200股，招商证券国际为独家保荐 人；预期H股将于2026年2月4日开始于联交所买卖。 ...